Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224158 | 0.85 | MET (0.37) | METKDR | |
| SCHEMBL307052 | 0.84 | MET (0.47) | METKDR | |
| SCHEMBL308179 | 0.82 | KDM5A (0.43) | METKDR | |
| SCHEMBL306441 | 0.79 | RAB9A (0.47) | METKDR | |
| SCHEMBL308535 | 0.78 | KDM4C (0.38) | METKDR | |
| SCHEMBL2532610 | 0.77 | MET (0.54) | METKDR | |
| SCHEMBL307608 | 0.76 | KDM5A (0.46) | METKDR | |
| SCHEMBL3573888 | 0.75 | MET (0.36) | METKDR | |
| SCHEMBL306285 | 0.75 | MET (0.43) | METKDR | |
| SCHEMBL13185375 | 0.75 | MET (0.35) | METKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-8455484-B2 | Selected inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-06-04 | — | — | US | disclosed |
| US-8455484-B2 | Selected inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-06-04 | — | — | US | disclosed |
| US-20110257175-A1 | Selected Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
| US-20110257175-A1 | Selected Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | MET 138/4885KDR 5/4885 |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | MET 49/4885KDR 2/4885 |
| US-20110257175-A1 | Selected Inhibitors of Protein Tyrosine Kinase Activity | ABL1, PRKDC, PRKACA | MET 669/4885KDR 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.